[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639986":3},{"organization":4,"outcomesModule":7,"designInfo":58,"detailedDescription":64,"studyPopulation":57,"armGroups":65,"interventions":72,"overallOfficials":57,"centralContacts":77,"locations":83,"responsibleParty":128,"collaborators":57,"id":132,"slug":57,"hasResults":133,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":57,"eligibilityCriteria":137,"healthyVolunteers":133,"sex":138,"minAge":139,"maxAge":140,"enrollmentInfo":141,"targetDuration":57,"studyType":144,"phases":145,"briefSummary":147,"conditions":148,"keywords":57,"overallStatus":86,"whyStopped":57,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":159},{"fullName":5,"class":6},"Chinese PLA General Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":20,"otherOutcomes":57},[9,13,17],{"measure":10,"description":11,"timeFrame":12},"Dose limited toxicity (DLT)","DLT is defined as any of the following adverse events (AEs) related to KSVCBD infusion occurring within 28 days after KSVCBD infusion","Within 28 days post-infusion",{"measure":14,"description":15,"timeFrame":16},"Incidence and severity of AEs and serious adverse events (SAEs)","AEs refer to any adverse medical events occurring in subjects from the initiation of KSVCBD administration during clinical trials. SAEs denote events involving death, life-threatening conditions, significant disability\u002Fincapacity, hospitalization or prolonged hospitalization arising after KSVCBD administration in subjects.","Within 24 months post-infusion",{"measure":18,"description":19,"timeFrame":16},"Incidence and severity of adverse events of special interest (AESI)","AESI including grade ≥ 3 Cytokine Release Syndrome (CRS), Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), and infections",[21,24,27,30,33,36,39,42,45,48,51,54],{"measure":22,"description":23,"timeFrame":16},"Objective Response Rate (ORR)","ORR includes Stringent Complete Remission (sCR), CR, Very Good Partial Remission (VGPR), and PR.",{"measure":25,"description":26,"timeFrame":16},"Minimal Residual Disease (MRD) negativity rate","Rate of achieving MRD negativity",{"measure":28,"description":29,"timeFrame":16},"≥ CR rate","Rate of achieving ≥ CR (CR and sCR)",{"measure":31,"description":32,"timeFrame":16},"Duration of Response (DOR)","Time from first documented PR or better to relapse or disease progression, or death from any cause",{"measure":34,"description":35,"timeFrame":16},"Time to Response (TTR)","Time from administration to first documented PR or better.",{"measure":37,"description":38,"timeFrame":16},"Progression-Free Survival (PFS)","Time from administration to disease progression or death from any cause, whichever occurs first.",{"measure":40,"description":41,"timeFrame":16},"Overall Survival (OS)","Time from administration to death from any cause.",{"measure":43,"description":44,"timeFrame":16},"KSVCBD lentiviral particle concentration","KSVCBD lentiviral particle concentration in peripheral blood.",{"measure":46,"description":47,"timeFrame":16},"Number of CAR-positive T cells","Number of CAR-positive T cells in peripheral blood.",{"measure":49,"description":50,"timeFrame":16},"CAR gene copy number","CAR gene copy number in peripheral blood.",{"measure":52,"description":53,"timeFrame":16},"Number of CD19-positive cells","Number of CD19-positive cells in peripheral blood.",{"measure":55,"description":56,"timeFrame":16},"Number of BCMA-positive cells","Number of BCMA-positive cells in peripheral blood.",null,{"allocation":59,"interventionModel":60,"interventionModelDescription":57,"primaryPurpose":61,"observationalModel":57,"timePerspective":57,"maskingInfo":62},"NA","SINGLE_GROUP","TREATMENT",{"masking":63,"maskingDescription":57,"whoMasked":57},"NONE","A structurally modified, third-generation, self-inactivating lentiviral vector was used in KSVCBD injection. This modified vector exhibits reduced immunogenicity and enables efficient T-cell targeting, thereby facilitating the in vivo generation of CD19\u002FBCMA CAR T cells from endogenous T cells. Simultaneously targeting BCMA to eliminate plasma cells producing anti-lentivirus and anti-CD19 scFv antibodies enables repeated infusion. The safety and efficacy of CD19\u002FBCMA dual-target autologous CAR-T therapy for the treatment of r\u002Fr MM have already been validated in clinical studies. In this study, dose-escalation research will be conducted to explore the safety and preliminary efficacy of CD19\u002FBCMA dual-target in vivo CAR-T therapy in patients with r\u002Fr MM who are positive for CD19 and\u002For BCMA expression.",[66],{"label":67,"type":68,"description":69,"interventionNames":70},"KSVCBD injection","EXPERIMENTAL","Administered by IV infusion",[71],"Biological: KSVCBD injection",[73],{"type":74,"name":67,"description":75,"armGroupLabels":76,"otherNames":57},"BIOLOGICAL","KSVCBD injection is an in vivo CAR-T therapy targeting CD19\u002FBCMA. Three dose levels are predefined, and KSVCBD will be dose-escalated per the protocol-specified doses",[67],[78],{"name":79,"role":80,"phone":81,"phoneExt":57,"email":82},"Weidong Han, M.D.","CONTACT","+86-010-55499341","hanwdrsw@sina.com",[84,106,115],{"facility":85,"status":86,"city":87,"state":88,"zip":89,"country":90,"countryCode":91,"cosmosGeoPoint":92,"geoPoint":97,"contacts":98},"Biotherapeutic Department of Chinese PLA General Hospital","RECRUITING","Beijing","Beijing Municipality","100853","China","CN",{"type":93,"coordinates":94},"Point",[95,96],116.39723,39.9075,{"lat":96,"lon":95},[99,101,104],{"name":79,"role":80,"phone":100,"phoneExt":57,"email":82},"+86-10-66937463",{"name":102,"role":103,"phone":57,"phoneExt":57,"email":57},"Yang Liu, M.D.","SUB_INVESTIGATOR",{"name":105,"role":103,"phone":57,"phoneExt":57,"email":57},"Jinhong Shi, M.S.",{"facility":107,"status":108,"city":87,"state":57,"zip":57,"country":90,"countryCode":91,"cosmosGeoPoint":109,"geoPoint":111,"contacts":112},"Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University","NOT_YET_RECRUITING",{"type":93,"coordinates":110},[95,96],{"lat":96,"lon":95},[113],{"name":114,"role":80,"phone":57,"phoneExt":57,"email":57},"Wen Gao, M.D.",{"facility":116,"status":108,"city":117,"state":57,"zip":57,"country":90,"countryCode":91,"cosmosGeoPoint":118,"geoPoint":122,"contacts":123},"National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College","Tianjin",{"type":93,"coordinates":119},[120,121],117.17667,39.14222,{"lat":121,"lon":120},[124,126],{"name":125,"role":80,"phone":57,"phoneExt":57,"email":57},"Lugui Qiu, M.D.",{"name":127,"role":103,"phone":57,"phoneExt":57,"email":57},"Gang An, M.D.",{"type":129,"investigatorFullName":130,"investigatorTitle":131,"investigatorAffiliation":5,"oldNameTitle":57,"oldOrganization":57},"PRINCIPAL_INVESTIGATOR","Han weidong","Director of Biotherapeutic Department","100639986",false,"NCT07620275","Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and\u002For BCMA","A Multicenter Clinical Study on the Safety and Efficacy of KSVCBD Injection in the Treatment of Multiple Myeloma With Positive Expression of CD19 and\u002For BCMA","Key Inclusion Criteria:\n\n1. Age 18-75 years (inclusive), any gender.\n2. Subjects must meet the following diagnostic and treatment criteria:\n\n   2.1 According to the IMWG 2014 diagnostic criteria, subjects must have a confirmed diagnosis of multiple myeloma and be in a relapsed or refractory state at screening, while meeting all of the following conditions:\n   * Must have received at least 3 prior lines of MM therapy (including a proteasome inhibitor and an immunomodulatory agent). consecutive cycles of induction chemotherapy, hematopoietic stem cell transplantation, and maintenance therapy are considered as one line of therapy if no disease progression occurs between these treatments. each line of therapy must consist of at least one complete treatment cycle, unless the best response to that regimen was disease progression.\n   * Must have experienced disease progression during or within 12 months after the most recent anti-myeloma therapy. or the subject must have experienced disease progression within the last 6 months and subsequently shown no response to the most recent line of therapy. Lack of response is defined as failure to achieve at least a minimal response (MR) or experiencing disease progression (PD) during treatment.\n\n   2.2 Subjects judged by the investigator to be intolerant to standard therapy may also be included in the study.\n3. Presence of measurable lesions at screening as determined by any of the following criteria:\n\n   * Serum monoclonal paraprotein (M-protein) level ≥ 1.0 g\u002FdL, or urinary M-protein level ≥ 200 mg\u002F24 hours. or\n   * For light chain multiple myeloma without measurable lesions in serum or urine: serum immunoglobulin free light chain level ≥ 10 mg\u002FdL and an abnormal serum immunoglobulin κ\u002Fλ free light chain ratio.\n4. Positive expression of CD19 and\u002For BCMA in tumor tissue confirmed by flow cytometry and\u002For histopathology (previous pathology or flow cytometry diagnosis of CD19 and\u002For BCMA in the patient, as confirmed by the investigator, is acceptable). For subjects who have previously received anti-CD19 and\u002For anti-BCMA therapy, a tumor biopsy should be performed to confirm current positive expression of CD19 and\u002For BCMA.\n5. Toxicities from any prior therapy must be stable and have resolved to ≤ Grade 1 (excluding hematologic toxicities and clinically insignificant toxicities such as alopecia).\n6. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.\n\nKey Exclusion Criteria:\n\n1. Expected survival \\\u003C 3 months.\n2. History of or concurrent active malignancy. Exceptions include: carcinoma in situ of the cervix that has been cured or with no recurrence for at least 3 years, non-invasive basal cell or squamous cell skin cancer, locally advanced prostate cancer that has received curative treatment, or ductal carcinoma in situ after radical surgery.\n3. Prior allogeneic hematopoietic stem cell transplantation (allo-HSCT) or autologous HSCT within 3 months prior to KSVCBD infusion.\n4. Solitary extramedullary soft tissue plasmacytoma.\n5. Diagnosis of plasma cell leukemia, Waldenström's macroglobulinemia, POEMS syndrome, or primary AL amyloidosis.\n6. Presence of CNS metastasis or symptoms of CNS metastasis.\n7. Receipt of anti-tumor therapy that is still within 5 half-lives prior to the planned KSVCBD infusion.\n8. Presence of uncontrolled active infections.\n9. Positive for human immunodeficiency virus (HIV) antibody, positive for Treponema pallidum antibody, positive for hepatitis B surface antigen (HBsAg) or positive for hepatitis B core antibody (HBcAb) with detectable peripheral blood HBV DNA, or positive for hepatitis C virus (HCV) antibody with detectable HCV RNA. except for infections that the investigator judges can be prevented or controlled with medication.\n10. Known active autoimmune disease requiring systemic treatment.\n11. Known severe allergy to the study drug or any of its components.\n12. Pregnant or breastfeeding women.\n13. Receipt of a live vaccine within 6 weeks prior to enrollment.","ALL","18 Years","75 Years",{"count":142,"type":143},9,"ESTIMATED","INTERVENTIONAL",[146],"PHASE1","KSVCBD injection is an in vivo Chimeric Antigen Receptor T-Cell (CAR-T cell) therapy product. This multicenter, single-arm, open-label, early exploratory clinical study is designed to evaluate the preliminary safety and efficacy of KSVCBD injection in patients with relapsed or refractory (r\u002Fr) multiple myeloma(MM) expressing CD19 and\u002For BCMA.",[149],"Multiple Myeloma","2026-05-27",{"date":152,"type":153},"2026-06-02","ACTUAL",{"date":155,"type":143},"2026-06-10",{"date":157,"type":143},"2029-03-15",{"name":5,"class":6},3]